DermTech, Inc., appointed Herman “Herm” Rosenman to its Board of Directors. Mr. Rosenman, CPA, brings more than 30 years of public company operating and financial experience to DermTech. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
Mr. Rosenman was most recently the Chief Financial Officer at Natera Inc., a prenatal genetic testing company, from January 2014 to January 2017. He was previously Senior Vice
President of finance and Chief Financial Officer of Gen-Probe Inc., where he was instrumental in its 2002 IPO and 2012 sale to Hologic Inc. for $3.7 billion. Prior to joining Gen-Probe, he was
president and chief executive officer of RadNet Management Inc., a large healthcare provider.

Before this, he was the chief financial officer of Rexene Corp., a Fortune 1000 company in the petrochemicals industry, where he led its successful $150 million IPO and $500 million debt
financing.

John Dobak, MD, CEO of DermTech commented, “I am extremely pleased to add Herm Rosenman to our Board of Directors. DermTech will benefit greatly from his years of experience
and success in genomics molecular testing.” Mr. Rosenman commented, “DermTech is one of the most exciting and innovative companies I have seen in my 30 years in the health care
industry. I look forward to joining the team and contributing to their success.”